Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06490328
PHASE3

Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

Sponsor: Dongkook Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

A phase 3, multi-center, single-group, open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer.

Official title: A Phase 3, Multi-center, Single-group, Open-label Study to Evaluate the Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

Key Details

Gender

MALE

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

161

Start Date

2024-05-30

Completion Date

2026-03-09

Last Updated

2026-08-14

Healthy Volunteers

No

Interventions

DRUG

DKF-MA102

Administered twice at 12-week intervals

Locations (8)

National Cancer Center

Gyeonggi-do, South Korea

Seoul National University Bundang Hospital

Gyeonggi-do, South Korea

Asan Medical Center

Seoul, South Korea

Ewha Womans University mokdong Hospital

Seoul, South Korea

Gangnam Severance Hospital, Yonsei University College of Medicine

Seoul, South Korea

Samsung Medical Center

Seoul, South Korea

Seoul National University Hospital

Seoul, South Korea

Seoul Saint. Mary's Hospital

Seoul, South Korea